<DOC>
	<DOCNO>NCT02228525</DOCNO>
	<brief_summary>The purpose study see selinexor improve blood count bone marrow function people type MDS .</brief_summary>
	<brief_title>Selective Inhibitor Nuclear Export ( SINE ) Selinexor ( KPT-330 ) Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Written inform consent accordance federal , local , institutional guideline Age ≥18 year Patients Myelodysplastic Syndromes refractory ( primary acquire resistance ) hypomethylating agent ( decitabine 5azacytidine ) . At least 4 1 month cycle prior decitabine SGI110 OR 6 1month cycle 5azacytidine ( IV , subcutaneous , oral require unless patient progressive disease prior complete require number cycle . Histologically confirm diagnosis Myelodysplastic Syndrome , meet criterion subtype FAB WHO classification system IPSS score . Patients MDS relapse allogeneic stem cell transplant eligible receive standard dose decitabine 5azacytidine prior stem cell transplant define inclusion criterion 3 . If patient undergone prior allogeneic stem cell transplant , must great 100 day post transplant ≤ grade 2 graftversushost disease There upper limit number prior treatment provide inclusion/exclusion criterion meet . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Patients receive erythropoietin ( darbepoetin , epoetin alfa ) must stable dose stable transfusion requirement hemoglobin level 8 week prior study entry . Adequate hepatic function within 21 day prior C1D1 : total bilirubin &lt; 2 time upper limit normal ( ULN ) , asparate aminotransferase ( AST ) &lt; 2.5 time ULN alanine aminotransferase ( ALT ) &lt; 2.5 time ULN . Adequate renal function within 21 day prior C1D1 : estimate creatinine clearance ≥ 30 mL/min , calculate use formula Cockcroft Gault . Female patient childbearing potential must agree use dual method contraception negative serum pregnancy test screening , male patient must use effective barrier method contraception sexually active female childbearing potential . Acceptable method contraception condom contraceptive foam , oral , implantable injectable contraceptive , contraceptive patch , intrauterine device , diaphragm spermicidal gel , sexual partner surgically sterilize postmenopausal . For male female patient , effective method contraception must use throughout study three month follow last dose . Patients pregnant lactating ; Chemotherapy immunotherapy anticancer therapy ≤3 week prior cycle 1 day 1 . Hydroxyurea may continue 72 hour prior first dose least 24 hour baseline bone marrow aspiration perform ; Major surgery within four week Day 1 ; Unstable cardiovascular function define symptomatic ischemia , uncontrolled clinically significant conduction abnormality ( ie : ventricular tachycardia antiarrhythmic exclude 1st degree AV block asymptomatic LAFB/RBBB exclude ) , congestive heart failure ( CHF ) NYHA Class ≥3 , myocardial infarction ( MI ) within 3 month ; Uncontrolled active infection require systemic antibiotic , antiviral , antifungal within one week prior first dose ; Prophylactic antimicrobial permit . Known HIV seropositive ; Known active hepatitis A , B , C infection ; know positive HCV RNA HBsAg ( HBV surface antigen ) ; Patients another active malignancy . Asymptomatic site disease consider active . Treated untreated site disease may consider inactive stable least 2 month expect require therapy 4 month . Patients significantly diseased obstruct gastrointestinal tract uncontrolled vomit diarrhea . Grade ≥2 peripheral neuropathy baseline ( within 21 day prior cycle 1 day 1 ) . History seizure , movement disorder cerebrovascular accident within past 1 year prior cycle 1 day 1 . Patients macular degeneration markedly decrease visual acuity , patient markedly decrease visual acuity ( specific etiology ) uncontrolled glaucoma . Patients significantly ideal body weight ( BMI &lt; 17 ) .. Serious psychiatric medical condition could interfere treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Selinexor ( KPT-330 )</keyword>
	<keyword>Selective Inhibitor Nuclear Export ( SINE )</keyword>
	<keyword>14-005</keyword>
</DOC>